REFERENCES
- Miller K. D., Chap L. I., Holmes F. A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 2005; 23: 792–799
- Relf M., LeJeune S., Scott P. A., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963–969
- Miller K. D., Wang M., Gralow J., et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100) (abstract 3). Presented at the 2005 San Antonio Breast Cancer Symposium, http://www.sabcs.com Available at Accessed June 7, 2007
- Miller K. D., Gradishar W., Moisa C., et al. Capecitabine plus bevacizumab in first line metastatic breast cancer: an interim safety and efficacy report of the first phase of xeloda plus avastin 1st line metastatic breast cancer trial (abstract 2068). Presented at the 2006 San Antonio Breast Cancer Symposium, http://www.sabcs.com Available at Accessed June 7, 2007
- Sledge G., Miller K., Moisa C., Gradishar W. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer (abstract 1013). Presented at the 2007 annual meeting of the American Society of Clinical Oncology, http://www.asco.org Available at Accessed June 7, 2007
- Hudis C. Drug Therapy: Trastuzumab. New England Journal of Medicine 2007; 357: 39–51
- Geyer C. E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England Journal of Medicine 2006; 355(26)2733–2743
- Solit D. B., Zheng F. F., Drobnjak M., et al. 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts. Clin. Cancer Res. 2002; 8(5)986–993
- Modi S., Stopeck A., Gordon M., et al. Trastuzumab and KOS-953 (17-AAG) is feasible and active in patients with metastatic breast cancer: preliminary results of a phase 1/2 study. Proc. SABCS 2005
- Miller K., Rosen L., Modi S., et al. Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T). Journal of Clinical Oncology ASCO Annual Meeting Proceedings Part I 2007; 25, (18S (June 20 Supplement) Abs 1115)
- Bendell J. C., Domchek S. M., Burstein H. J., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972–2977
- Lin N. U., Bellon J. R., Winer E. P. CNS metastases in breast cancer. J. Clin. Oncol. 2004; 22: 3608–3617
- Rivera E., Meyers C., Groves M., et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 107: 1348–1354